IL2 and myelodysplastic syndrome: Given that NK cells in MDS are susceptible to the TGF-β-mediated suppression while also being responsive to the IL-2 activation, a clinical trial combining NK cells, IL-2, and the TGF-β inhibitor Vactosertib is currently being conducted across various malignancies, including MDS (NCT05400122).